Net profit of Supriya Lifescience rose 57.03% to Rs 46.78 crore in the quarter ended December 2024 as against Rs 29.79 crore during the previous quarter ended December 2023. Sales rose 32.54% to Rs 185.65 crore in the quarter ended December 2024 as against Rs 140.07 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales185.65140.07 33 OPM %35.5229.62 - PBDT67.5444.07 53 PBT62.5840.11 56 NP46.7829.79 57 Powered by Capital Market - Live News

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live News

Supriya Lifescience  inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately Rs 125 crore, adds a substantial capacity of 335 kiloliters to the company`s operations. This expansion boosts its Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.Powered by Capital Market - Live News

Net profit of Supriya Lifescience rose 93.26% to Rs 46.15 crore in the quarter ended September 2024 as against Rs 23.88 crore during the previous quarter ended September 2023. Sales rose 18.56% to Rs 166.10 crore in the quarter ended September 2024 as against Rs 140.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales166.10140.10 19 OPM %38.9622.66 - PBDT66.8133.76 98 PBT62.0729.78 108 NP46.1523.88 93 Powered by Capital Market - Live News

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live News